CA2345248C - Use of prostanoid antagonists for the treatment of primary headache disorders - Google Patents

Use of prostanoid antagonists for the treatment of primary headache disorders Download PDF

Info

Publication number
CA2345248C
CA2345248C CA002345248A CA2345248A CA2345248C CA 2345248 C CA2345248 C CA 2345248C CA 002345248 A CA002345248 A CA 002345248A CA 2345248 A CA2345248 A CA 2345248A CA 2345248 C CA2345248 C CA 2345248C
Authority
CA
Canada
Prior art keywords
treatment
antagonists
antagonist
headache
primary headache
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002345248A
Other languages
English (en)
French (fr)
Other versions
CA2345248A1 (en
Inventor
Gordon Smith Baxter
Robert Alexander Coleman
Nicholas Tilford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Precision for Medicine UK Labs Ltd
Original Assignee
Asterand UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asterand UK Ltd filed Critical Asterand UK Ltd
Publication of CA2345248A1 publication Critical patent/CA2345248A1/en
Application granted granted Critical
Publication of CA2345248C publication Critical patent/CA2345248C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2807—Headache; Migraine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Slide Fasteners, Snap Fasteners, And Hook Fasteners (AREA)
  • Medicines Containing Plant Substances (AREA)
CA002345248A 1997-09-25 1998-09-25 Use of prostanoid antagonists for the treatment of primary headache disorders Expired - Fee Related CA2345248C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9720270.9A GB9720270D0 (en) 1997-09-25 1997-09-25 Medicaments for the treatment of migraine
PCT/GB1998/002895 WO2000018405A1 (en) 1997-09-25 1998-09-25 Use of prostanoid antagonists for the treatment of primary headache disorders

Publications (2)

Publication Number Publication Date
CA2345248A1 CA2345248A1 (en) 2000-04-06
CA2345248C true CA2345248C (en) 2008-03-18

Family

ID=26312305

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002345248A Expired - Fee Related CA2345248C (en) 1997-09-25 1998-09-25 Use of prostanoid antagonists for the treatment of primary headache disorders

Country Status (12)

Country Link
US (1) US8513027B2 (https=)
EP (1) EP1115404B1 (https=)
JP (1) JP2002525327A (https=)
AT (1) ATE257707T1 (https=)
AU (1) AU757265B2 (https=)
CA (1) CA2345248C (https=)
DE (1) DE69821142T2 (https=)
DK (1) DK1115404T3 (https=)
ES (1) ES2213914T3 (https=)
GB (2) GB9720270D0 (https=)
PT (1) PT1115404E (https=)
WO (1) WO2000018405A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720270D0 (en) 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
AU3445100A (en) * 2000-03-24 2001-10-08 Pharmagene Lab Ltd Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists
US20050059742A1 (en) * 2001-10-31 2005-03-17 Jabbour Henry Nicolas Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of dysmenorrhea and menorphagia
WO2003072138A1 (en) * 2002-02-26 2003-09-04 Ortho-Mcneil Pharmaceutical Inc. Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
EP2846793A1 (en) 2012-05-09 2015-03-18 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2028805B (en) 1978-07-11 1982-11-03 Glaxo Group Ltd Prostanoid compounds
JPS5718671A (en) 1980-04-30 1982-01-30 Glaxo Group Ltd Aminocyclopentane alkenoic acid and esters thereof,manufacture and drug composition
US4839384A (en) 1988-10-07 1989-06-13 E. R. Squibb & Sons, Inc. Method of inhibiting onset of or treating migraine headache using a thromboxane A2 receptor antagonist
ES2133324T3 (es) 1991-05-03 1999-09-16 Searle & Co Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso.
US5182272A (en) 1991-05-03 1993-01-26 G. D. Searle & Co. 8-substituted-dibenz[b,f][1,4]oxazepine-10(11)-carboxylic acid, substituted hydrazides, pharmaceutical compositions, and methods for treating pain
US5212169A (en) 1991-10-31 1993-05-18 G. D. Searle & Co. Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treating pain
CA2118688A1 (en) 1991-11-05 1993-05-13 Timothy J. Hagen Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
WO1993013082A1 (en) 1991-12-20 1993-07-08 G.D. Searle & Co. Substituted dibenzoxazepines or dibenzothiazepines and their use as prostaglandin e2 antagonists
US5266571A (en) 1992-01-09 1993-11-30 Amer Moh Samir Treatment of hemorrhoids with 5-HT2 antagonists
US5395932A (en) 1993-04-30 1995-03-07 G. D. Searle & Co. 2,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5488046A (en) 1993-11-03 1996-01-30 G. D. Searle & Co. Carbamic acid derivatives of substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
CA2179399A1 (en) 1993-12-20 1995-06-29 Kiyoshi Taniguchi 4,5-diaryloxazole derivatives
WO1995024393A1 (en) 1994-03-10 1995-09-14 Fujisawa Pharmaceutical Co., Ltd. Naphthalene derivatives as prostaglandin i2 agonists
TW401408B (en) 1995-07-21 2000-08-11 Fujisawa Pharmaceutical Co Heterocyclic compounds having prostaglandin I2 agonism
AUPO713297A0 (en) 1997-06-02 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Oxazole compound
US20030158240A1 (en) 1998-09-25 2003-08-21 Pharmagene Laboratories Limited Methods for the treatment of primary headache disorders using prostanoid EP4 receptor antagonists, and assays for agents for such treatment
GB9720270D0 (en) 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
EP1071648A2 (en) 1998-03-13 2001-01-31 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
AU1444200A (en) 1998-10-15 2000-05-01 Merck & Co., Inc. Methods for inhibiting bone resorption
DE60012751T2 (de) 1999-08-10 2005-01-20 Glaxo Group Ltd., Greenford Verwendung von EP 4 Rezeptorliganden zur Behandlung von neuropathischem Schmerz
EP1742662A2 (en) 2004-05-03 2007-01-17 Astellas Pharma Inc. Combination of prostaglandin e2 receptor antagonists and renin-angiotensin system inhibitors for treating renal diseases

Also Published As

Publication number Publication date
CA2345248A1 (en) 2000-04-06
PT1115404E (pt) 2004-05-31
DK1115404T3 (da) 2004-04-13
GB2341799A (en) 2000-03-29
US20080247954A1 (en) 2008-10-09
WO2000018405A1 (en) 2000-04-06
GB2341799B (en) 2000-08-16
DE69821142D1 (de) 2004-02-19
DE69821142T2 (de) 2004-11-11
AU757265B2 (en) 2003-02-13
EP1115404B1 (en) 2004-01-14
US8513027B2 (en) 2013-08-20
GB9820936D0 (en) 1998-11-18
EP1115404A1 (en) 2001-07-18
JP2002525327A (ja) 2002-08-13
ES2213914T3 (es) 2004-09-01
ATE257707T1 (de) 2004-01-15
GB9720270D0 (en) 1997-11-26
AU9177698A (en) 2000-04-17

Similar Documents

Publication Publication Date Title
AU783165B2 (en) Compositions and methods for treating female sexual dysfunction
CN1325304A (zh) 用于治疗偏头痛的5ht1受体激动剂和甲氧氯普胺
US5693654A (en) Medicaments for treating intraocular pressure
CA2415577C (en) Use of cox-2 inhibitors for preventing immunodeficiency
Mazaleuskaya et al. Druggable prostanoid pathway
US8513027B2 (en) Method of identifying an inhibitor of the prostanoid EP4 receptor
GB2330307A (en) EP4 Receptor antagonists as bone resorption inhibitors
EP1267867B1 (en) Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists
IE912237A1 (en) Pharmaceutical preparations
AU2000234451A1 (en) Use of prostanoid EP4 receptor antagonists for the treatment of headache and assays for such antagonists
EP0433043A1 (en) Medicaments
JP2010047583A (ja) 原発性頭痛障害の治療のためのプロスタノイドアンタゴニストの使用
US20030158240A1 (en) Methods for the treatment of primary headache disorders using prostanoid EP4 receptor antagonists, and assays for agents for such treatment
US5770610A (en) Melatonin agonists for use in the treatment of benign prostatic hyperplasia (BPH)
US20030018031A1 (en) Formulations of 5HT agonists
US6265429B1 (en) Method for treating congestive heart failure
AU2001270902B2 (en) Use of COX-2 inhibitors for preventing immunodeficiency
HK1055087B (en) Use of cox-2 inhibitors as immunostimulants in the treatment of hiv or aids
ZA200300446B (en) Use of cox-2 inhibitors for preventing immunodeficiency.
MXPA01004297A (en) 5ht1

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140925